# Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

> **NCT00334893** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 74 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Primary Peritoneal Cavity Cancer
- Recurrent Ovarian Epithelial Cancer

## Interventions

- **DRUG:** eribulin mesylate

## Key facts

- **NCT ID:** NCT00334893
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2017-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00334893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00334893, "Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00334893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*